Complete AAV Production System Enables Scalable Gene Therapy Workflows
CARLSBAD, Calif., Sept. 20, 2021 /PRNewswire/ --Addressing the need to make adeno-associated virus (AAV) production more efficient and scalable, Thermo Fisher Scientific has launched the integrated Gibco AAV-MAX Helper Free AAV Production System*, a complete, optimized solution that simplifies the AAV vector production workflow.
- CARLSBAD, Calif., Sept. 20, 2021 /PRNewswire/ --Addressing the need to make adeno-associated virus (AAV) production more efficient and scalable, Thermo Fisher Scientific has launched the integrated Gibco AAV-MAX Helper Free AAV Production System*, a complete, optimized solution that simplifies the AAV vector production workflow.
- AAV is crucial to the field of gene therapy; more than 1,300 unique gene therapy products are currently under development, and nearly half are reliant on AAV.The ability to scale production is critical to bringing down costs and accelerating the process from research to commercialization.
- "The new AAV production system is part of our end-to-end workflow solutions designed to meet growing demand for cost-effective, scalable viral vector production.
- To learn more about the Gibco AAV-MAX Helper Free AAV Production System, please visit www.thermofisher.com/aavmax .